Focusing on genetic polymorphisms implicated in the dopaminergic pathway, which is central to PD pathology, no significant effect of DRD3, DRD4, SLC, or MAO-A polymorphisms on the inverse smoking-PD risk was noted. The gene discussed is CCL21; the disease is Parkinson disease.